Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Pharma in her DNA, Wockhardt scion ready for deep dive in the US
Zahabiya Khorakiwala is leading Wockhardt's US business and the launch of its new antibiotic, Zaynich. This drug targets resistant bacterial infections and is a significant bet for the company. Zaynich's US approval marks a major breakthrough after decades without new antibiotics. Zahabiya is focused on hospital penetration, physician advocacy, and demonstrating economic value to healthcare systems.
Buy, Sell Or Hold: Wockhardt, Sagility, UCO Bank, Groww And Sammaan Capital — Ask Profit
Market experts shared buy, sell and hold recommendations for an array of stocks.
Ahead of Market: 10 things that will decide stock market action on Tuesday
Benchmark indices Sensex and Nifty fell for a fourth straight session amid elevated crude oil prices, geopolitical tensions and persistent selling pressure. Market breadth remained weak, technical indicators turned bearish, while select stocks including Wockhardt and NMDC Steel attracted buying interest and hit fresh highs.
Buy, Sell Or Hold: Suzlon, Wockhardt, Natco Pharma, JSW Infra, HDFC Bank, Zaggle — Ask Profit
Buy Sell Hold
FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics market
Wockhardt’s newly approved antibiotic Zaynich has the potential to transform the treatment of drug-resistant infections, according to Mahesh Patel, the scientist behind the drug. Approved by the US FDA for complicated urinary tract infections, Zaynich combines cefepime and zidebactam, using a novel “beta-lactam enhancer” mechanism that blocks two key steps in bacterial cell-wall synthesis, helping it overcome virtually all known resistance mechanisms.
Wockhardt hits all-time high on CDSCO approval for antibiotic Zaynich
The buying on the counter came after the company received approval from the CDSCO for the import and marketing of Zaynich Zidebactam/Cefepime
Supriya Lifescience Ltd leads gainers in 'A' group
Relaxo Footwears Ltd, Wockhardt Ltd, Netweb Technologies India Ltd and Ashapura Minechem Ltd are among the other gainers in the BSE's 'A' group today, 29 May 2026.
Godrej Consumer Products Ltd leads losers in 'A' group
KPIT Technologies Ltd, Arvind Fashions Ltd, Brigade Enterprises Ltd and Wockhardt Ltd are among the other losers in the BSE's 'A' group today, 07 May 2026.
Small & midcaps rally! Wockhardt, Coforge, other stocks surge up to 14%. Do you own any?
Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by strong earnings reports, a fall in oil prices, and renewed market optimism. Key gainers included Coforge, SRF, and Wockhardt, driven by significant profit increases and strategic investments.
Top Gainers & Losers on May 5: Wockhardt, Tata Tech, Gabriel India, Dabur, Adani Green Energy among top gainers - Mint
Top Gainers & Losers on May 5: Wockhardt, Tata Tech, Gabriel India, Dabur, Adani Green Energy among top gainersMint
Wockhardt Ltd leads gainers in 'A' group
Quess Corp Ltd, Computer Age Management Services Ltd, Tata Technologies Ltd and CreditAccess Grameen Ltd are among the other gainers in the BSE's 'A' group today, 05 May 2026.
Smallcap winners! Wockhardt, Tata Tech, CAMS, other stocks rally up to 11% despite overall market weakness
Smallcap stocks outperformed on Tuesday despite weak broader markets, with Wockhardt, Tata Tech and CAMS gaining up to 11% on strong Q4 earnings. While Nifty 50 slipped below 24,000 amid global concerns, improving momentum and technical indicators signal potential continued strength in the smallcap segment, according to Emkay.